Ag平台·(中国区)集团官方网站
About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Pipelines
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Career
Now Hiring
简
|
EN
|
Akeso News
Monthly News
2022-04-26
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-04-26
Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-04-26
Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-03-08
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
2022-03-02
Akeso Announces Clinical Trial Collaboration with Chipscreen Biosesciences to evalsuate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer
2022-02-11
AKESO’S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)
2021-11-02
PD-1/VEGF BI-SPECIFIC ANTIBODY (AK112) OBTAINED APPROVAL TO INITIATE A PHASE II CLINICAL TRIAL FOR MONOTHERAPY OR COMBINED CHEMOTHERAPY...
2021-10-22
Akeso, Inc. Doses First Patient in a Clinical Study of Anti-TIGIT Monoclonal Antibody (AK127) in Combination with Cadonilimab (Anti-PD-1/CTLA-4) for Treatment of Advanced or Metastatic Solid Tumors
2021-10-18
Akeso Will Publish Six Latest Research Results at the SITC 2021
2021-10-12
Rapid Advancement of Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
2021-10-11
AK112 (PD-1/VEGF Bi-Specific Antibody) in Combination with AK117 (CD47 Monoclonal Antibody) Obtained Approval to Initiate Clinical Trial for the Treatment of Advanced Malignant Tumors
2021-10-05
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate Clinical Trial for the Treatment of Advanced Triple-Negative Breast Cancer
«
3
4
5
6
7
8
9
10
11
»
网站首页
